MarketPulse

pancreatic cancer

11 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Revolution Medicines

Revolution Medicines' Daraxonrasib Achieves NEJM Publication on Pancreatic Cancer Progress

Revolution Medicines published Phase 1/2 daraxonrasib data in NEJM, demonstrating promising activity in RAS mutant pancreatic cancer and supporting Phase 3 trial initiation.
RVMDRVMDWclinical trial resultspancreatic cancer
GlobeNewswire Inc.GlobeNewswire Inc.··Theriva Biologics

Theriva Biologics Advances VCN-01 Pancreatic Cancer Program With Phase 3 FDA Approval

Theriva Biologics will present expanded VIRAGE trial data for VCN-01 at AACR 2026, with FDA and EMA agreement on Phase 3 design for metastatic pancreatic cancer treatment.
TOVXFDA approvalPhase 3 trial
GlobeNewswire Inc.GlobeNewswire Inc.··Na

AIM ImmunoTech Flags Going Concern Despite Clinical Trial Progress

AIM ImmunoTech disclosed going concern warnings in 2025 audited statements but expressed confidence in fundraising backed by promising Ampligen-Imfinzi trial results.
AZNAIMPhase 2 clinical trialfundraising
BenzingaBenzinga··Vandana Singh

Revolution Medicines Soars 40% on Pancreatic Cancer Breakthrough, Despite Merck Deal Collapse

Revolution Medicines surges 40% after Phase 3 trial shows daraxonrasib doubles survival in metastatic pancreatic cancer versus chemotherapy.
MRKRVMDRVMDWPhase 3 trialclinical trial results
BenzingaBenzinga··Akanksha Bakshi

Profusa Surges 135% on PanOmics Acquisition Push Into Booming Diagnostics Market

Profusa acquires BioInsights' PanOmics platform in all-equity deal, gaining $30M equity boost and expanding into multi-billion precision diagnostics market. Stock surges 135% on strategic expansion.
PFSAacquisitioncommercialization
GlobeNewswire Inc.GlobeNewswire Inc.··Renovorx, Inc.

RenovoRx Lands Fast Company's Top 10 Innovative Medical Device Firms Amid RenovoCath Momentum

RenovoRx ($RNXT) earns Fast Company recognition as #10 innovative medical device firm, with $1.1M RenovoCath sales and Phase III pancreatic cancer trial advancing toward mid-2026 enrollment completion.
RNXTtargeted oncologyPhase III trial
BenzingaBenzinga··Nabaparna Bhattacharya

AIM ImmunoTech Surges 73% on Japanese Patent Victory for Cancer Therapy

AIM ImmunoTech ($AIMT) surged 73.66% after securing Japanese patent approval for Ampligen cancer therapy through 2039, strengthening its immuno-oncology portfolio.
AIMintellectual propertyorphan drug designation
GlobeNewswire Inc.GlobeNewswire Inc.··Na

AIM ImmunoTech Closes $1.8M Rights Offering to Fund Pancreatic Cancer Drug

AIM ImmunoTech closes $1.8M rights offering to advance Ampligen immunotherapy development for late-stage pancreatic cancer treatment.
AIMclinical trialswarrants
BenzingaBenzinga··Globe Newswire

AIM ImmunoTech Raises $1.8M Through Rights Offering as Biotech Seeks Capital

AIM ImmunoTech raises $1.8M through rights offering expiring March 3, 2026, providing working capital for ongoing immunotherapy operations.
AIMwarrantscapital raise
GlobeNewswire Inc.GlobeNewswire Inc.··Can-Fite Biopharma Ltd.

Can-Fite's Namodenoson Clears Safety Hurdle in Pancreatic Cancer Study

Can-Fite's namodenoson meets primary safety endpoint in Phase IIa pancreatic cancer trial with no new safety signals; survival data pending.
CANFclinical developmentorphan drug designation
BenzingaBenzinga··Prnewswire

Biotech Pipeline Expands Arsenal Against Treatment-Resistant Cancers

Biotech firms advance treatment-resistant cancer therapies across multiple platforms, including oncolytic viruses and cellular immunotherapy, with several candidates achieving regulatory milestones and encouraging clinical data.
IBRXONCYNVCRCATXNUVBcolorectal cancerFDA approval